Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Marra

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Cancer Journal (Sudbury, Mass.)|January 21, 2021
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With ChemotherapyAntonio Marra, Giuseppe Curigliano
NPJ Breast Cancer|September 5, 2019
Are all cyclin-dependent kinases 4/6 inhibitors created equal?Antonio Marra, Giuseppe Curigliano
BMC Medicine|May 10, 2019
Recent advances in triple negative breast cancer: the immunotherapy eraAntonio Marra, Giulia Viale, Giuseppe Curigliano
European Journal of Cancer (Oxford, England : 1990)|May 8, 2020
The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy RegionDario Trapani, Antonio Marra, Giuseppe Curigliano
Nature Reviews. Clinical Oncology|January 9, 2024
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Translational Cancer Research|February 4, 2022
Toward precision medicine in inflammatory breast cancerGiulia Viale, Antonio Marra, Giuseppe Curigliano, et al.
Cancer Treatment and Research|January 4, 2024
Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast CancerAntonio Marra, Dario Trapani, Emanuela Ferraro, et al.
Current Opinion in Oncology|August 25, 2023
Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancerGrazia Castellano, Federica Giugliano, Giuseppe Curigliano, et al.
NPJ Breast Cancer|October 22, 2020
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesAntonio Marra, Dario Trapani, Giulia Viale, et al.
Cancer Treatment Reviews|March 2, 2021
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary qualityPaolo Tarantino, Luca Mazzarella, Antonio Marra, et al.
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Cancer Journal (Sudbury, Mass.)|January 21, 2021
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With ChemotherapyAntonio Marra, Giuseppe Curigliano
NPJ Breast Cancer|September 5, 2019
Are all cyclin-dependent kinases 4/6 inhibitors created equal?Antonio Marra, Giuseppe Curigliano
BMC Medicine|May 10, 2019
Recent advances in triple negative breast cancer: the immunotherapy eraAntonio Marra, Giulia Viale, Giuseppe Curigliano
European Journal of Cancer (Oxford, England : 1990)|May 8, 2020
The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy RegionDario Trapani, Antonio Marra, Giuseppe Curigliano
Nature Reviews. Clinical Oncology|January 9, 2024
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Translational Cancer Research|February 4, 2022
Toward precision medicine in inflammatory breast cancerGiulia Viale, Antonio Marra, Giuseppe Curigliano, et al.
Cancer Treatment and Research|January 4, 2024
Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast CancerAntonio Marra, Dario Trapani, Emanuela Ferraro, et al.
Current Opinion in Oncology|August 25, 2023
Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancerGrazia Castellano, Federica Giugliano, Giuseppe Curigliano, et al.
NPJ Breast Cancer|October 22, 2020
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesAntonio Marra, Dario Trapani, Giulia Viale, et al.
Cancer Treatment Reviews|March 2, 2021
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary qualityPaolo Tarantino, Luca Mazzarella, Antonio Marra, et al.
Pageof 11